View Clinical Trial (Medical Research Study)
Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
| City: |
|
Nashville |
| State: |
|
Tennessee |
| Zip Code: |
|
37205 |
| Conditions: |
|
Multiple Myeloma |
| Purpose: |
|
Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis.
Carfilzomib is a novel proteasome inhibitor with activity in this setting. Panobinostat is
a pan-deacetylase inhibitor which has shown synergistic cytotoxicity in vitro and in vivo
with proteasome inhibitors. The combination should enhance the activity of both agents
against myeloma cells. In the Phase I part of the trial, the optimal doses of the
combination of carfilzomib and panobinostat will be determined. Assuming this combination
is feasible, the Phase II portion will proceed, using the doses determined in Phase I. This
trial will be conducted at multiple study sites by the Sarah Cannon Research Institute
(SCRI) Oncology Research Consortium.
|
| Study Summary: |
|
This is an open-label; non-randomized Phase I/II study of patients with relapsed or
refractory multiple myeloma.
The Phase I study will determine the MTD of the combination of carfilzomib and panobinostat.
The Phase I portion will follow a standard dose escalation design, beginning with dose
level 1 (see Table 2). Patients will be assessed for dose-limiting toxicity (DLT) at each
visit during Cycle 1 prior to receiving treatment. Dose modifications will not be permitted
during Cycle 1 unless a patient experiences a DLT (see Section 5.2.2.). Treatment cycles
will be administered at 28-day intervals. Panobinostat will be administered orally three
times weekly during weeks 1 and 3 of each cycle (Days 1, 3, 5, 15, 17, 19). Carfilzomib
will be administered intravenously on Days 1, 2, 8, 9, 15, and 16 of each cycle. During
Cycle 1, the carfilzomib dose will be escalated after the Day 2 dose, if well tolerated.
A maximum of three dose levels will be evaluated.Approximately 24 patients will be enrolled
during the Phase I portion to establish the MTD.
In the Phase II portion of this study, patients with relapsed/refractory multiple myeloma
will receive treatment with the panobinostat and carfilzomib combination established during
Phase I. Patients will be reevaluated for response to treatment after each cycle (4
weeks). Patients with objective response or stable disease will continue treatment, with
subsequent reevaluations every 4 weeks, until disease progression or unacceptable toxicity
occurs.
Up to 54 eligible patients will be treated in the Phase I/II study.
|
| Criteria: |
|
Inclusion Criteria:
1. Eligible participants must have multiple myeloma using standard criteria (Appendix
B).
2. Patients must have measurable disease requiring systemic therapy defined as at least
one of the following:
- Serum M-protein >/=1 g/dl (>/=10 g/l)
- Urine M-protein >/=200 mg/24 hrs
- Serum free light chain assay: involved free light chain level >/=10 mg/dl
(>/=100 mg/l) provided the serum free light chain ratio is abnormal
3. Must have progressed during or after at least one previous bortezomib-containing
treatment regimen. Patients who have received previous high-dose therapy/autologous
stem cell transplantation are eligible.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (See Appendix
A).
5. Must meet the following laboratory criteria:
- Absolute neutrophil count (ANC) >/=1000/μL;
- Platelets >/=70,000/microL;
- AST or ALT and alkaline phosphatase (ALP) must be </=2.5 x ULN, or </=5 x ULN in
patients with plasmacytomas of the liver;
- Total bilirubin </=1.5 x the institutional ULN;
- Serum creatinine </=1.5 x ULN or calculated creatinine clearance >/=50 ml/min;
- Serum potassium, calcium, magnesium WNL (These may be corrected prior to
starting therapy, to make the patient eligible.)
6. Ability to swallow oral medications.
7. Baseline MUGA or ECHO must demonstrate left ventricular ejection fraction (LVEF) >/=
the lower limit of the institutional limits of normal.
8. Male or females >/=years of age.
9. Female patients must not be of child-bearing potential or must agree to use
adequate contraceptive measures.
10. Male patients willing to use adequate contraceptive measures.
11. Willingness and ability to comply with the trial and follow-up procedures.
12. Ability to understand the nature of this trial and give written informed consent.
Exclusion Criteria:
1. Currently receiving or have received systemic cancer therapy (chemotherapy, biologic
therapy) </=21 days of initiating study therapy. For patients receiving small
molecule targeted therapy, study treatment may begin >21 days after last dose or >5
half lives of previous treatment, whichever is shorter. Patients must have completed
radiation therapy >/=ays prior to starting study treatment. Patients must have
recovered from or come to a new chronic stable baseline from all treatment-related
toxicities. Dexamethasone or other high-dose steroid therapy must be stopped >/=ays
prior to starting study treatment.
2. Previous treatment with HDAC, DAC, HSP90 or valproic acid for treatment of cancer.
3. Requires valproic acid for any medical condition during the study ≤5 days prior to
first panobinostat treatment.
4. Patient has not recovered from all therapy-related toxicities associated with prior
treatments to < Grade 2 CTCAE.
5. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
carfilzomib).
6. Patients with pleural effusions requiring thoracentesis or ascites requiring
paracentesis </=14 days prior to study entry.
7. Patients using medications that have a risk of prolonging the QT interval or inducing
Torsade de Pointes if treatment cannot be discontinued or switched to a different
medication prior to receiving study drug (see Appendix F).
8. Patients with > grade 2 diarrhea.
9. Patients with impaired cardiac function, including any of the following conditions:
- History or presence of sustained ventricular tachyarrhythmia.
- Any history of ventricular fibrillation or Torsade de pointes.
- Bradycardia defined as HR <50 bpm. Patients with pacemakers are eligible if HR
>/=bpm.
- Screening ECG with a QTc >450 msec.
- Right bundle branch block + left anterior hemiblock (bifascicular block).
- Patients with myocardial infarction or unstable angina </=6 months prior to
starting study drug.
- Other clinically significant heart disease (e.g. CHF NY Heart Association class
III or IV (Appendix D), uncontrolled hypertension, history of labile
hypertension, or history of poor compliance with an antihypertensive regimen).
10. Infection requiring IV antibiotics.
11. Patients with > grade 2 peripheral neuropathy or with uncontrolled pain.
12. Women who are pregnant or lactating.
13. Any concurrent medical illness that may impair the ability of the patient to tolerate
study treatment and comply with the requirements of the study.
14. Mental condition that would prevent patient comprehension of the nature of, and risk
associated with, the study.
15. Use of any non-approved or investigational agent </=30 days prior to administration
of the first dose of study drug. Patients may not receive any other investigational
or anti-cancer treatments while participating in this study.
16. Presence of other active cancers, or history of treatment for invasive cancer </= 5
years. Patients with stage I cancer who have received definitive local treatment at
least 3 years previously, and are considered unlikely to recur are eligible. All
patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible,
as are patients with history of non-melanoma skin cancer.
|
| NCT ID: |
|
NCT01496118 |
| Primary Contact: |
|
Study Chair
Jesus Berdeja, MD
Sarah Cannon Research Institute
Jesus Berdeja, MD
Phone: 1-877-691-7274
Email: asksarah@scresearch.net
|
| Backup Contact: |
|
Email: trialsinfo@scresearch.net
Trials Info
Phone: 615-329-7274
|
| Location Contact: |
|
Nashville, Tennessee 37205
United States
Lee Ann Potts, RN
Phone: 877-691-7274
Email: ASKSARAH@scresearch.net
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 17, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|